JAMA dermatology最新文献

{"title":"Infantile Hemangiomas.","authors":"Flora E Bradley, Erin F D Mathes","doi":"10.1001/jamadermatol.2026.0412","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.0412","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Risk in Patients With Overall and Site-Specific Lichen Planus.","authors":"Cecilia Egede Medianfar, Emma L Kaderly Rasmussen, Louise Baandrup, Tatiana Hansen, Rasmus Hertzum-Larsen, Merete Hædersdal, Susanne K Kjær","doi":"10.1001/jamadermatol.2026.3933","DOIUrl":"10.1001/jamadermatol.2026.3933","url":null,"abstract":"<p><strong>Importance: </strong>The association between lichen planus (LP) and subsequent cancer risk, particularly by anatomical site, is not well established.</p><p><strong>Objective: </strong>To assess the association between any LP, and site-specific LP, and the subsequent risk of cancer compared to the general population.</p><p><strong>Design, settings, and participants: </strong>This was a retrospective cohort study using nationwide Danish register-based data of individuals with an incident LP diagnosis (1978-2020), with no prior cancer, identified through the National Patient Register (any LP) and the Danish Pathology Register (any LP and site-specific LP). Data were analyzed from August 20 to December 20, 2025.</p><p><strong>Exposures: </strong>Any diagnosis of LP independent of site, and LP at specific anatomical sites (oral, cutaneous, and genital).</p><p><strong>Main outcomes and measures: </strong>Participants were followed up for incident cancer outcomes until death, emigration, or December 31, 2023. Cancers were identified through the Danish Cancer Register. Standardized incidence ratios (SIRs) with 95% CIs were calculated separately for females and males, comparing cancer incidence in patients with LP to the general Danish female or male population.</p><p><strong>Results: </strong>A total of 35 845 patients with LP (21 650 females and 14 195 males) were included in the analysis. Compared to the general population, females with any LP had increased risk of oral cancers (lip, SIR = 6.0; 95% CI, 3.3-10.0; oral cavity, SIR = 7.5; 95% CI, 6.4-8.9; tongue, SIR = 6.8; 95% CI, 5.4-8.4) and vulvar cancer (SIR = 2.6; 95% CI, 2.0-3.4), while the risk of squamous cell carcinoma was slightly elevated (SIR = 1.4; 95% CI, 1.3-1.6). In contrast, lung cancer risk was decreased (SIR = 0.7; 95% CI, 0.6-0.8). Results were consistent across follow-up. The cancer risk pattern was similar in male patients with LP. Site-specific analyses showed the highest risk of oral cancers in patients with oral LP, and of genital cancer in patients with genital LP. The 20-year absolute risks in female and male patients were 0.8% (95% CI, 0.7%-1.0%) and 1.0% (95% CI, 0.8-1.2) for oral cavity cancers, 0.5% (95% CI, 0.4%-0.6%) and 0.6% (95% CI, 0.5%-0.8%) for tongue cancers, 0.1% (95% CI, 0%-0.1%) and 0.2% (95% CI, 0.1%-0.3%) for lip cancers, and 0.4% (95% CI, 0.2%-0.5%) and 0.2% (95% CI, 0.1%-0.2%) for genital cancers, respectively.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, LP was associated with markedly increased risks of oral and genital cancers, as well as a slightly increased risk of skin cancer, particularly at sites corresponding to the anatomical LP location. While the absolute risk is low, site-specific cancer should be considered a possible long-term complication of LP.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data Errors in Abstract and Main Results, Figure 1, and Table 2.","authors":"","doi":"10.1001/jamadermatol.2026.4149","DOIUrl":"10.1001/jamadermatol.2026.4149","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papulonodules and Lymphadenopathy in a Man in His 30s.","authors":"Yao Xu, Shanglin Jin, Chengfeng Zhang","doi":"10.1001/jamadermatol.2026.3736","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3736","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial.","authors":"Bingyang Xu, Jiali Chu, Ye Wang, Yuanqin Wang, Liuyun Li, Yan Yang, Biao Yu, Tong Xiao, Peiwen Yang, Na Wu, Hong Sun, Shengxiang Xiao, Yumin Xia, Peng An, Tianxiao Zhang, Jiawen Wu","doi":"10.1001/jamadermatol.2026.3999","DOIUrl":"10.1001/jamadermatol.2026.3999","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Transcutaneous auricular vagus nerve stimulation is effective for rosacea. However, its neuroimmunomodulatory effects lack sham-controlled serum biochemical evidence, and specialized device reliance limits its clinical popularization.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the clinical efficacy of device-free auricular acupressure for rosacea and verify its neuroimmunomodulatory effects using serum biomarkers and immediate vascular imaging in a sham-controlled trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This single-center, randomized, sham-controlled, assessor-masked trial was conducted in the Dermatology Outpatient Department of the Second Affiliated Hospital of Xi'an Jiaotong University from October 2025 to May 2026 and included 204 patients with rosacea who were receiving standard first-line treatment. Participants were assigned in a 1:1 ratio using block randomization. Data analysis was initiated in May 2026.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;The active acupressure group received a Vaccaria segetalis seed on the bilateral cavum conchae (innervated by the auricular vagus branch), while the sham group received a seed on the auricular tubercle superior margin (pure somatosensory innervation). Participants performed acupressure 3 times daily for 30 seconds, with extra pressing allowed during acute flare-ups. The intervention lasted 8 weeks. Serum levels of cathelicidin antimicrobial peptide (LL-37), calcitonin gene-related peptide (CGRP), tumor necrosis factor α (TNF-α), and interleukin (IL) 6 were measured at baseline and week 8. Multispectral imaging was performed at baseline and week 4 to assess immediate vascular responses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was treatment success, defined as an Investigator Global Assessment (IGA) score of 0 or 1 at week 8. The number needed to treat was calculated from absolute risk difference.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The 204 participants were equally divided into 2 groups (102 each; active acupressure: mean [SD] age, 32.51 [10.60] years, 86 female individuals [84.3%]; sham acupressure: mean [SD] age, 30.82 [9.32] years, 86 female individuals [84.3%]). At week 8, the active acupressure group had a higher IGA success rate (58 [56.9%] vs 36 [35.3%]; relative risk, 1.61; 95% CI, 1.18-2.20; P = .003; number needed to treat, 5). Serum LL-37, CGRP, TNF-α, and IL-6 levels decreased more significantly in the active acupressure group. The immediate vascular improvement rate was 59.3% vs 7.4% (P &lt; .001). At week 20, the active acupressure group maintained significantly lower IGA and Clinical Erythema Assessment scores. No serious adverse events occurred.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This randomized clinical trial found that device-free, on-demand intervention yielded substantial additional clinical benefits when combined with standard first-line therapy and established early sham-controlled,","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Acne Vulgaris From 1990-2023 and Forecasts to 2050.","authors":"Pierina Parraga, Justin Tang, John S Barbieri","doi":"10.1001/jamadermatol.2026.3943","DOIUrl":"10.1001/jamadermatol.2026.3943","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in Incidence Rates and Other Numbers in Study of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.","authors":"Ali Al-Janabi","doi":"10.1001/jamadermatol.2026.4172","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4172","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflation-Adjusted Medicare Reimbursement for Common Dermatologic Procedures.","authors":"Joshua A Kent, Celine M Schreidah, Daniel C Malone, Larisa J Geskin","doi":"10.1001/jamadermatol.2026.3849","DOIUrl":"10.1001/jamadermatol.2026.3849","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma Prevention Among Children of Melanoma Survivors: A Randomized Clinical Trial.","authors":"Yelena P Wu, Tammy K Stump, Pascal R Deboeck, Liberty A Woodside, Juliana Moyano, Jennifer L Hay, Lisa G Aspinwall, Kenneth M Boucher, Douglas Grossman, Kathi Mooney, Sancy A Leachman, Ken R Smith, Samuel E Hancock, Ali P Wankier, Kenneth P Tercyak","doi":"10.1001/jamadermatol.2026.3877","DOIUrl":"10.1001/jamadermatol.2026.3877","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Children of melanoma survivors have a 2-fold increased lifetime risk of melanoma, yet they inconsistently practice sun protection and experience preventable sunburns.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate a telehealth-delivered behavioral intervention for skin cancer prevention among children of melanoma survivors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This parallel-group randomized clinical trial assigned survivor-child dyads to the family, lifestyles, actions, and risk education (FLARE) intervention or a control condition between April 2020 and October 2023. Participants were recruited through a cancer registry and statewide and clinical databases. Eligible survivors had a confirmed melanoma diagnosis and at least 1 child aged 8 to 17 years with 1 or more sunburns during the previous year. Of 520 eligible survivors, 364 dyads enrolled, completed baseline assessment, and were randomized. Data were analyzed from 2025 to 2026.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Both conditions were telehealth education modules delivered over 4 weeks. FLARE included familial melanoma risk education and skills building that targeted child sun protection. The control included general skin cancer education on identifying reputable sources of health information.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was child sunburn occurrence, which was evaluated as the change from baseline through the 2 postintervention assessments. Secondary outcomes included child sun-protective behaviors and tanning.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 364 survivor-child dyads were recruited and randomized (parents: mean [SD] age, 45.1 [6.2] years; 228 female individuals [62.6%]; children: mean [SD] age, 12.9 [2.6] years; 189 female individuals [51.9%]). The primary analysis, which included 364 dyads (180 FLARE [49.5%], 184 control [50.5%]) in the intention-to-treat analyses, found no significant between-group differences in rate of sunburn change across time. However, at the first postintervention assessment, child-reported sunburn occurrence was lower in the FLARE group compared with the control group (B = -0.17; 95% CI, -0.30 to -0.04; P = .01). Relative to the control group, FLARE participants demonstrated greater increases in child sun-protective behaviors from baseline through the second postintervention assessment (B = 0.26; 95% CI, 0.14-0.38; P &lt; .001). No significant between-group differences were observed for intentional or unintentional tanning, which were infrequently reported at baseline.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this randomized clinical trial, FLARE failed to reduce child sunburn over time compared with an active educational control. Although FLARE improved sun-protective behaviors and was associated with lower child-reported sunburn immediately postintervention, additional strategies may be needed for sustained reductions in high-risk children.&lt;/p&gt;&lt;p&gt;&lt;s","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome.","authors":"Gabriele Roccuzzo, Abraham Bashir, Felicity Evison, Sean Whittaker, Martine Bagot, Emmanuella Guenova, Evangelia Papadavid, Henry Miles Prince, Jose A Sanches, Denis R Miyashiro, Octavio Servitje, Christiane Querfeld, Oleg Akilov, Arvind Arumainathan, Luke Bennett, Maxime Battistella, Mike Bayne, Silvia Alberti Violetti, Paolo Fava, Christoph Iselin, Marie Beylot-Barry, Anne Marie Busschots, Richard Cowan, Reinhard Dummer, Giles Dunnill, Teresa Estrach, Larisa Geskin, Alejandro A Gru, Joan Guitart, Melba C Herrera, Emmilia Hodak, Steve Horwitz, Constanze Jonak, Claus-Detlev Klemke, Robert Knobler, Pam Mckay, Marta Marschalkó, Cesare Massone, Rubeta N Matin, Christina Mitteldorf, Robert Novoa, Pablo Ortiz-Romero, Nicola Pimpinelli, Ramon M Pujol, Kerri E Rieger, Rudolf Stadler, Franz Trautinger, Johanna Latzka, Maarten Vermeer, Rachel Wachsmuth, Sophie Weatherhead, Ulrike Wehkamp, Marion Wobser, Pietro Quaglino, Youn H Kim, Julia Scarisbrick","doi":"10.1001/jamadermatol.2026.3856","DOIUrl":"10.1001/jamadermatol.2026.3856","url":null,"abstract":"<p><strong>Importance: </strong>Risk stratification in advanced mycosis fungoides and Sézary syndrome (MF/SS) remains suboptimal given that current TNMB (tumor, node, metastasis, blood) staging has limited prognostic value for clinically relevant outcomes.</p><p><strong>Objective: </strong>To determine whether the Cutaneous Lymphoma International Prognostic Index (CLIPI) may be used to predict progression-free survival (PFS) and best objective response (BOR) in patients with advanced MF/SS.</p><p><strong>Design, setting, and participants: </strong>This international prospective cohort study included patients with stage IIB to IVB MF/SS from the PROCLIPI trial which ran from July 1, 2015, to May 1, 2025, across 46 referral centers. Median follow-up was 4.75 (95% CI, 4.04-5.13) years; eligible participants had complete data on CLIPI, PFS, and BOR. Data were analyzed from September 1 to December 1, 2025.</p><p><strong>Exposure: </strong>CLIPI score at diagnosis, based on age (>60 years), elevated serum lactate dehydrogenase, N3 nodal status, and large-cell transformation in the skin. Patients were classified as having low (0 or 1 factor), intermediate (2 factors), or high risk (3 or 4 factors).</p><p><strong>Main outcomes and measures: </strong>PFS (defined as diagnosis to disease progression or death) and BOR (complete response, partial response, stable disease, or progressive disease) during follow-up. Exploratory analyses evaluated treatment effects before progression using inverse probability weighting.</p><p><strong>Results: </strong>Among 277 patients (median [IQR] age at diagnosis, 66 [23-89] years; 183 male individuals [65.7%]), 144 (52.0%) were classified as having low risk, 93 (33.6%) intermediate risk, and 40 (14.4%) high risk. They had a median PFS of 4.64 years (95% CI, 3.50-5.76), 2.72 years (95% CI, 1.81-4.56), and 0.89 years (95% CI, 0.65-1.14), respectively (log-rank P < .001). Patients in the intermediate-risk (hazard ratio [HR], 1.45; 95% CI, 1.01-2.08) and high-risk (HR, 3.84; 95% CI, 2.21-6.66) CLIPI groups displayed higher hazards of progression or death than those at low risk. Inclusion of CLIPI improved PFS discrimination over a model with baseline stage alone. Each 1-point increase in CLIPI was associated with approximately 38% lower odds of observing a better response during follow-up (odds ratio, 0.62; 95% CI, 0.43-0.89).</p><p><strong>Conclusions and relevance: </strong>In this international prospective cohort of patients with advanced MF/SS, CLIPI scores were associated with risk of disease progression and likelihood of response beyond clinical stage. These findings indicate that CLIPI may help to refine risk stratification and support its integration into clinical decision-making and future trial design.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}